Jackson Financial heads into its May 6 Q1 earnings release with options traders at their most defensive in at least a year.
The clearest signal is in the put/call ratio, which has climbed to 1.55 — its highest reading of the past 52 weeks and roughly 1.5 standard deviations above its 20-day average of 1.31. That jump has been sharp and sustained, with the PCR trending higher for the better part of three weeks. The stock itself closed at $108.47 on Tuesday, down 4.4% on the day and 6.1% on the week, even as it retains a modest 4.6% gain over the past month. Correlated peers told a different story on Tuesday: EQH gained 6.1% and CRBG added 5.1%, while JXN moved in the opposite direction — a divergence that sharpened the options skew heading into the print.
Short interest adds a layer of caution without screaming alarm. It has risen roughly 19% over the past month to 4.6% of the free float, with a 4.4% weekly gain bringing it to approximately 3.1 million shares. Days to cover run at 5.5. The lending market, however, offers little sign of pressure: availability remains extremely loose, with borrow running at just 2% of the pool, well off the 52-week high of 6.4%. Cost to borrow is a minimal 0.32%, actually easing from recent highs near 0.49%. The short positioning looks measured rather than aggressive — a hedge rather than a directional bet.
The analyst picture is mixed heading in. Barclays holds an Overweight rating with a $136 target — still implying meaningful upside from current levels — while Keefe, Bruyette & Woods trimmed its target modestly to $120 in early April, maintaining a Market Perform view. Evercore ISI carries an Underperform. The Street is divided on whether Jackson's exposure to variable annuities and equity market sensitivity is a feature or a flaw at current valuations. The forward EPS growth trajectory ranks in the 99th percentile on a year-over-year basis, yet EPS surprise scores rank near the bottom of the universe at the 6th percentile — a tension that frames the bull-versus-bear debate neatly: can the company translate a favourable macro tailwind into a genuine beat, or will results once again disappoint relative to setup? The stock's P/E of 4.6x and price-to-book of 0.71x suggest the market is pricing in scepticism, not optimism.
The print will test whether Jackson's Q1 results justify the options market's unusually defensive lean — or close the gap between JXN's recent underperformance and the recovery seen across its closest peers.
See the live data behind this article on ORTEX.
Open JXN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
